Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct 8:40:101880.
doi: 10.1016/j.eucr.2021.101880. eCollection 2022 Jan.

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

H Mohammad  1 , K Madsen  2   3 , O Graumann  4   5 , A C Loya  6   7 , N V Jensen  1 , R H Dahlrot  1   5
Affiliations
Case Reports

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

H Mohammad et al. Urol Case Rep. .

Abstract

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

Keywords: Metanephric adenoma; Oncology; Renal tumour; Tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CT from 2010 with intravenous contrast. Tumour is seen in the left kidney (white arrow).
Fig. 2a
Fig. 2a
Overview of the tumour in relation to surrounding renal parenchyma (HE, x 2.5).
Fig. 2b
Fig. 2b
Close-up of the tumour with visible acinar and papillary structures (HE, x20).
Fig. 2c
Fig. 2c
Proliferation marker.
Fig. 3a
Fig. 3a
CT from 2017 with intravenous contrast. Large cystic mass is seen with solid component contrast enhancing (white arrow).
Fig. 3b
Fig. 3b
CT from 2018 with intravenous contrast. Soft tissue process in the left kidney's bed (white arrow).
See this image and copyright information in PMC

References

    1. Davis C., Barton J., Sesterhenn I. Clinicopathological study of fifty patients. Am J Surg Pathol. 1995;19(10):1101–1114. - PubMed
    1. Pins M., Jones E., Martul V., Kamat B., Unlas J., Renshaw A. Metanephric adenoma- like tumor of the kidney. Report of 3 malignancies with emphasis on discriminating features. Arch Pathol Lab Med. 1999;123(5):415–420. - PubMed
    1. Choueiri T., Cheville J., Palescandolo E. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012;62(5):917–922. - PMC - PubMed
    1. Brown J.A., Anderl K.L., Borell T.J., Qian J., Bostwick D.G., Jenkins R.B. Simultaneous chromosome 7 and 17 gain and sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma. J Urol. 1997;158:370–374. - PubMed
    1. Renshaw A.A., Freyer D.R., Hammers Y.A. Metastatic metanephric adenoma in a child. Am J Surg Pathol. 2000;24(4):570–574. - PubMed

Publication types

LinkOut - more resources